review of glp 1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 receptor agonists show promise

In the aforementioned trials, except the REWID trial, the most represented patients were those with established cardiovascular diseases, indicating that efficacy of GLP-1 receptor agonists is proven in terms of secondary prevention

glargine, both combined with lispro, mitigated eGFR decline in people with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)

Ong LT, Sia CH (2025) Interactions between antidiabetes medications and heart-brain axis

You get marketing graphics instead of real data

Rubino F, Cummings DE, Eckel RH, et al

But as millions of patients rely on these medicines, consistent manufacturing quality and transparency become even more important